tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Immutep (IMMP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNYResearch Report) and Immutep (IMMPResearch Report) with bullish sentiments.

Alnylam Pharma (ALNY)

Needham analyst Joseph Stringer maintained a Buy rating on Alnylam Pharma today and set a price target of $240.00. The company’s shares closed last Wednesday at $202.21, close to its 52-week high of $212.00.

According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.6% and a 30.6% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Lexicon Pharmaceuticals.

Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $199.13, implying a -5.2% downside from current levels. In a report issued on July 28, RBC Capital also maintained a Buy rating on the stock with a $225.00 price target.

See the top stocks recommended by analysts >>

Immutep (IMMP)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Immutep yesterday and set a price target of $8.00. The company’s shares closed last Wednesday at $2.30, close to its 52-week low of $1.85.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -41.9% and a 10.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Immutep has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More